PPT-SOF/VEL + GS-9857 N = 33

gt 18 years Genotype 2 3 4 5 or 6 HCV RNA gt 10 000 IUmL Treatmentnaive or treatmentexperienced with or without DAA Compensated cirrhosis allowed Creatinine clearance gt 60 mLmin. 400/100 mg . qd. N = 120. N = 120. W12. SOF + RBV. > . 18 years. Chronic HCV infection. Genotype . 2. Naïve . or pre-treatment. with IFN-based regimen. Compensated cirrhosis allowed**. No HBV or HIV co-infection. 400/100 mg . qd. N = 500. N = 100. W12. Placebo. >. 18 years. Chronic HCV infection. Genotype 1, 2, 4, 5 or 6. Naïve or pre-treatment. with IFN-based regimen. Compensated cirrhosis allowed**. No HBV or HIV co-infection. HCV WORLD CAB .  FEBRUARY 2014. BANGKOK, THAILAND. When to Treat HCV. . HCV Direct-Acting . Antivirals. (. DAAs. ) in . development. . OVERVIEW. Know your epidemic: what matters. N = 69. >. 18 years. Failure to SOF/VEL . or SOF/VEL + VOX . (LEPTON study). Any genotype. Compensated cirrhosis allowed. No HBV or HIV co-infection. Open-label. SOF/VEL: 400/100 mg FDC QD ; RBV: weight based in twice daily dose . N = 12. N = 13. W24. W16. SOF + EBR + GZR + RBV. > . 18 years. HCV infection. G. enotype 1 or 4. Failure to a prior therapy with . SOF ± RBV + (SMV or DCV or LDV) . with documented presence of . NS5A or NS3 RASs at failure . Open-label. Chronic HCV infection. Genotype 1 . Failure to achieve SVR. 12. . on a short-course of 1. st. line. LDV/SOF-containing regimen . No cirrhosis. N = 34. SVR. 12. Co-formulated ledipasvir-sofosbuvir (LDV 90 mg/SOF 400 mg) : 1 pill qd. SOF + SMV + RBV. SOF + SMV. Randomisation. 2 : 1 : 2 : 1*. Open-label. * . Randomisation. was stratified on genotype (1a or 1b) in both cohorts, . IL28B . in cohort 1 and treatment history (naïve or non-responder) in cohort . SOF + RBV. Randomisation*. 1 : 1 : 1. Open-label. BOSON . Study. : SOF + RBV . +. PEG-IFN . for genotypes 2 and 3. ≥ 18 years. Chronic HCV infection. Genotype 2, treatment-experienced with cirrhosis. 400/100/100 mg QD. N = 263. N = 152. W12. Placebo. >. 18 years. Chronic HCV infection. Genotype 1, 2, 3, 4, 5 or 6. NS5A inhibitor-experienced . for ≥ 4 weeks (exclusion if . discontinued due to an adverse. . and. . Longer. Wagon . for. European Transportation. Dipl.-Ing. A. Carrillo Zanuy. EC FP7-SST-2010-RTD-1. Collaborative Project, Nr. 265610. Duration: 25 M . (01.12.2010-31.12.2012). 4 Partners: . 12. (HCV RNA < 25 IU/ml), . with. 95% CI. DCV 60 mg . qd. SOF 400 mg . qd. DCV 60 mg . qd. SOF 400 mg . qd. Not randomised. Open. -label. ALLY-3 . Study. : DCV SOF for HCV genotype 3. W12. Wargaming Div, MCWL, Quantico. Updated 10 Jan 2005 (see speaker notes for details). VMA. 3. HIDE. 3-16FA. A. ENY. CG47. Introduction. Comments. Table of Contents. 208. X. 100. 0. 151500Z. PHOENIX. B. W24. SOF/VEL. >. 18 years. Chronic HCV infection. Genotype 1 to 6. Naïve or treatment-experienced. No prior treatment with . NS5A or NS5B inhibitor. Child-Pugh B cirrhosis **. No . hepatocellular. April 10. –14. , 2019. Vienna, Austria. Disclaimer. These non-promotional slides are intended to be used as educational material only in response to an unsolicited question or request. The double-dagger (.